Results 1 to 10 of about 1,776,183 (353)

The deleted in brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src [PDF]

, 2007
The transmembrane receptor 'ROR2' resembles members of the receptor tyrosine kinase family of signalling receptors in sequence but its' signal transduction mechanisms remain enigmatic.
A Schambony, AJ Mikels, AR Afzal, Faraz Khosravi Mardakheh, GC Schwabe, H Hikasa, H van Bokhoven, I Oishi, I Oishi, J Billiard, J Liu, John K. Heath, JP Gorvel, K Alexandropoulos, Lee M. Wheldon, M Miaczynska, M Nishita, M Oldridge, M Sammar, MR Larsen, P Masiakowski, R Ishizawar, Richard Steinhardt, S Stricker, S Takeuchi, SA Beausoleil, Shiva Akbarzadeh, Sonia Talma, Steve M. M. Sweet, TM DeChiara, WC Forrester, Y Liu, Z Songyang   +32 more
core   +21 more sources

The SYK tyrosine kinase: a crucial player in diverse biological functions

Nature Reviews Immunology, 2010
Attila Mócsai, Jürgen Ruland, Victor L J Tybulewicz   +2 more
exaly   +2 more sources

Targeting Bruton's tyrosine kinase in B cell malignancies

Nature Reviews Cancer, 2014
Rudi W Hendriks, Saravanan Y Pillai
exaly   +2 more sources

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Journal of Hematology & Oncology, 2020
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then ...
Liling Huang, Shiyu Jiang, Yuankai Shi
semanticscholar   +1 more source

The tyrosine kinase Csk dimerizes through Its SH3 domain. [PDF]

PLoS ONE, 2009
The Src family kinases possess two sites of tyrosine phosphorylation that are critical to the regulation of kinase activity. Autophosphorylation on an activation loop tyrosine residue (Tyr 416 in commonly used chicken c-Src numbering) increases catalytic
Nicholas M Levinson, Patrick R Visperas, John Kuriyan   +2 more
doaj   +1 more source

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report

Cancer Treatment and Research Communications, 2021
Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors.
Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb   +2 more
doaj   +1 more source

A Combination of L-Triiodothyronine and Levothyroxine in the Treatment of Tyrosine Kinase Inhibitor-Induced Hypothyroidism in Renal Cell Carcinoma: A Case Report. [PDF]

Clin Case Rep
Han YJ, Chen S, Miao R, Yu ZY, Wang YB.
europepmc   +3 more sources

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj   +1 more source

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials

Journal of Xenobiotics, 2023
Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti-D antibodies are the commonly used initial treatments for ITP.
Muhammad Ashar Ali, Muhammad Yasir Anwar, Wajeeha Aiman, Gurneel Dhanesar, Zainab Omar, Mohammad Hamza, Maha Zafar, Harish Kumar Rengarajan, Michael Maroules   +8 more
doaj   +1 more source